Klimurtan

Bosentan, the active ingredient in Klimurtan, is an endothelin receptor antagonist presented as an oral tablet for oral administration. It works by blocking endothelin receptors to cause vasodilation of pulmonary vessels, and is indicated for the treatment of pulmonary arterial hypertension in adult patients.

GNH USA supplies Klimurtan as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and reliable global distribution. All shipments are handled under strict temperature‑controlled conditions where required.

Klimurtan (bosentan) acts on the endothelin pathway to manage pulmonary arterial hypertension.

- Idiopathic pulmonary arterial hypertension: improves exercise capacity and delays disease progression. - Heritable pulmonary arterial hypertension: reduces pulmonary vascular resistance and enhances functional class. - Pulmonary arterial hypertension associated with connective tissue disease: improves hemodynamics and patient symptoms.

Bosentan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often reported during treatment. - Peripheral edema: swelling of the lower extremities. - Flushing: transient redness of the skin. - Nasal congestion: stuffy nose or runny nose. - Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Anemia: reduction in red blood cell count leading to fatigue. - Pulmonary edema: fluid accumulation in lungs, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure causing dizziness.

Before prescribing bosentan, clinicians should consider several safety measures and monitoring requirements. - Liver function monitoring: check ALT, AST, bilirubin before and during therapy. - Hemoglobin assessment: monitor for anemia regularly. - Contraindication in pregnancy: avoid use as it is teratogenic (Category X). - Severe hepatic impairment: do not use in patients with significant liver disease. - Drug interaction with glyburide: avoid co‑administration due to increased hypoglycemia risk. - Store below 25°C: keep in the original pack, protect from moisture.

Bosentan interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase bosentan plasma concentrations and risk of toxicity. - Glyburide: concurrent use can cause severe hypoglycemia. - Combined endothelin antagonists: additive risk of liver injury.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce bosentan effectiveness. - Amiodarone: may increase bosentan levels modestly. - Hormonal contraceptives: bosentan may lower their efficacy, requiring alternative contraception.